Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Impact of COVID-19 pandemic on pediatric patients with epilepsy in Jordan: The caregiver perspective

Miral Al Momani a,⁎, Basima A. Almomani b, Philip Sweidan c, Aladdin Al-Qudah d, Samah Aburahma e, Yusra Arafeh c

⁎ Department of Pediatrics and Neonatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan
b Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan
c Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan
d Department of Conservative Dentistry, Faculty of Dentistry, Jordan University of Science and Technology, Irbid, Jordan
e Department of Neuroscience, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan

A R T I C L E   I N F O
Keywords:
COVID-19
Pandemic
Epilepsy
Children
Seizure control

A B S T R A C T
Objectives: The recent COVID-19 pandemic has disrupted care systems around the world. We assessed the impact of COVID-19 lockdown on the care of pediatric patients with epilepsy in Jordan. Potential predictors for seizure control during COVID-19 outbreaks were investigated.
Methods: A cross-sectional survey was conducted on pediatric patients with epilepsy in Jordan, between January and February 2021, via online questionnaires. The collected data included demographic information, epilepsy-related characteristics, views of caregivers and changes in seizure control during COVID-19 outbreak.
Results: A total number of 672 subjects were screened, 276 were eligible, and 154 completed the questionnaire adequately. Two thirds of caregivers (66.2%) reported that the COVID-19 outbreaks prevented their child from getting proper epilepsy care and 28.6% reported difficulty giving the drugs to their child on time because of loss of daily routine. In addition, more than half (55.8%) reported difficulty obtaining antiseizure medicines (ASMs). On the other hand, 77.3% of caregivers reported that seizure status remained unchanged or improved for their children during the COVID-19 and 22.7% reported worsened seizure control. The number of antiseizure medicines taken by patients (p < 0.001), age (p = 0.032), residency area (p = 0.013) and the difficulty in giving the medicine during COVID-19 pandemic (p = 0.002) were the major factors influencing the seizure worsening experienced by patients.
Conclusion: Almost one of every five patients reported worsened seizure control during the outbreak of COVID-19 in Jordan. Moreover, two thirds of caregivers reported poor epilepsy care. This finding highlights the need to implement organized and efficient telemedicine programs devoted to epilepsy care.

1. Introduction

Coronavirus disease 2019 (COVID-19) is a communicable disease caused by the newly emergent SARS-COV-2. The literature was able to uncover several aspects of respiratory and non-respiratory manifestations [2]. Neurological manifestations have been frequently encountered and documented [11]. Mild complaints of anosmia and ageusia have been used to distinguish contracting COVID-19 from the seasonal flu [12]. The most commonly reported serious neurological manifestations in young low-risk patients included encephalitis and strokes [8]. People with chronic illness are a vulnerable population because they are at a higher risk for severe illness from COVID-19. Epilepsy is documented to be the second-greatest neurological disorder burden worldwide [18]. Moreover, findings indicate that severe and potentially injurious seizure behaviors contribute to anxiety and socially avoidant behavior for people with epilepsy [7].

The first COVID-19 case in Jordan was reported on March the 2nd 2020. This was followed by spikes in September and October 2020 [10]. Accordingly, the focus of health services was directed towards COVID-19 management, leaving out abundant numbers of patients...
without their regular access to health care. This entailed trouble getting their medicines due to several factors including fear of contracting the infection, financial strain, and psychological depression. Around 70% of children with epilepsy with optimal treatment would enter remission if access to medications and regular follow-up were attainable [15]. However, in reality, remission has been difficult to maintain due to the barriers to care that are present during the outbreak.

A study by Rosengard and coworkers in the USA assessed the adult patient’s perceived seizure control during the pandemic and reported that 17.5% of responders suffered from worsening seizure control with the majority having more frequent attacks [18]. While other patients with epilepsy suffered from more severe seizures or new-onset seizures [18]. Moreover, both stress (80.6%) and poor sleep attributed to the pandemic were the most reported seizure precipitants by patients with epilepsy [18]. Furthermore, impaired access to epilepsy care including difficulty obtaining antiseizure medicines was more likely to be documented among those who reported worsened seizure control [18]. Another study from Italy that investigated the impact of COVID-19 on patients with epilepsy, reported an increased seizure frequency in 13.2% of patients [19]. In Jordan, focal epilepsies were the most common type of pediatric epilepsy, the structural-metabolic causes were the most common causes of epilepsy [1]. Adding to that, epilepsy originating from genetic causes was commonly attributed to electroclinical syndromes [1]. In contrast to patients with epilepsy from other Arab countries, those from Jordan appear to exhibit the best overall life quality, mainly due to good seizure control [4]. Moreover, a pre-pandemic study in Jordan stated that most of the adult patients with epilepsy did not have any restriction of daily activities due to epilepsy. In addition, more than half of them did not perceive any impact of epilepsy on their daily living [4]. Worldwide, there’s a prominent paucity of information regarding the impact of the COVID-19 pandemic on epilepsy [3].

The main goal of this study was to assess the influence of the COVID-19 outbreak on seizure control among pediatric patients with epilepsy in Jordan and whether specific variables (demographics, epilepsy characteristics, and healthcare access) were associated with this change. In addition, the views of patients’ caregivers on different issues related to the COVID-19 pandemic were investigated.

2. Methods and materials

2.1. Study design

A cross-sectional survey was conducted on pediatric patients with epilepsy in Jordan during January and February 2021. The online questionnaire was developed using Google Forms and distributed to patients using WhatsApp. A second reminder was sent to those who did not respond to the first message. The list of candidate patients who were diagnosed with epilepsy within the last 5 years (2016-2020) at King Abdullah University Hospital was retrieved from a computerized hospital database. These patients were registered in the pediatric neurology clinic at the hospital. The current study included pediatric patients with epilepsy aged 1-16 years who had their diagnosis confirmed by a neurology consultant, regularly visited the clinic, and were treated with antiseizure medicines for at least 6 months. Newly diagnosed patients, first attack of seizure, those with EEG-confirmed psychogenic non-epileptic seizures (PNEs), Dravet syndrome, and SCN1A phenotypes were excluded from the study. Ethical approval was granted from the Institutional Review Board in Jordan University of Science and Technology. Consent to participate in the study was obtained from participants before filling the questionnaire. Approximately, a total of 10 minutes was required to complete the online survey.

2.2. Questionnaire development

The questionnaire items were developed based on literature review [9, 10] and discussion within the research team. The questionnaire was originally constructed in English and reviewed for face validity by experts in the field. Following that, it was translated to Arabic and examined for clarity through a pilot study (n=5). The questionnaire consisted of 3 main sections covering different themes. The first section covered demographic details such as age, gender, monthly income, residence place, and educational level. The second section included information about epilepsy history such as duration of epilepsy, type of epilepsy, number of anti-seizure medications, and seizure exacerbation during the COVID-19 pandemic. The third section covered the views of caregivers during the COVID-19 outbreak (in terms of access to healthcare services along with possible concerns they had during the pandemic in regard to their child’s health).

2.3. Data analysis

After data collection, all the submitted questionnaires were checked for completeness and entered into SPSS. Descriptive statistics of categorical (counts and percentages) and continuous (median and interquartile range) variables were calculated. Univariate analyses were conducted using the appropriate statistical tests (chi-square, Mann Whitney) to assess the association between the variables and seizure control. Factors that were investigated as potential predictors for seizure control during COVID-19 were: age of the child, gender, duration of disease, education of caregivers, income, insurance, employment, achievement of seizure control before the outbreak, difficulty getting antiseizure medicines during the pandemic, number of antiseizure medicines, years of medication treatment, difficulty getting medicinal coasto your child, type of epilepsy, and presence of the comorbid condition. Factors with < 0.05 on univariate analyses were entered in multivariate analysis using binary logistic regression to calculate odds ratio (OR) and 95% confidence interval (95%CI). The statistical significance level was considered at a p-value < 0.05.

3. Results

3.1. Demographics

Out of 672 patients in the hospital list, 396 were excluded because of having a new-onset seizure, first attack of seizure, not on antiseizure medicine or febrile seizure. Of 276 eligible patients whose caregivers were contacted: 91 did not respond, 2 were reported dead and 10 declined participation. A total number of 173 patients’ caregivers filled the survey and a total of 154 complete responses were recorded and included in the analysis.

The average age of children was 10 years old, and more than half of the children were males (55.2%). Approximately, half of the patients’ caregivers had school education (52.6%), 47.4% were employed and 74% had a monthly income less than 600 JOD. Moreover, 49.4% of patients were living in a village and a third (36.4%) of patients were not medically insured.

Regarding clinical data; 22.1% of patients had comorbid conditions (such as meningomyelecele, hypothyroidism, iron deficiency anemia, heart failure, failure to thrive, bronchial asthma, mild immune deficiency, diabetes mellitus ……etc). The average duration of epilepsy among patients was 3 years and 44.2% of them had focal epilepsy. A half of patients (51.3%) used 2 or more antiseizure medicines and 61.7% reported no change on antiseizure medicines (dose, duration, type of medication) during COVID-19. Only 1.9% reported that their child with epilepsy had tested positive for COVID-19. However, 12.3% stated that their children might have been infected with COVID-19 without confirming this by any laboratory testing. Detailed demographics and clinical are presented in Table 1.
3.3. Level of seizure control of patients with epilepsy during COVID-19

77.3% of caregivers reported that seizure status remained unchanged or improved for their children during COVID-19 and 22.7% reported worsened seizure control. The results of multivariate analysis are shown in Table 3. The results indicated that patients with ≥ 2 ASMs had worsened seizure control compared to those who were taking one medication (OR=10.512, 95%CI=3.105-35.587, p < 0.001). In addition, caregivers who found difficulty in giving ASMs to their child had worsened seizures compared to their counterparts (OR=7.114, 95%CI=2.004-25.259, p = 0.002). Furthermore, those living in a village had worsened seizures compared to those living in a city (OR=3.585, 95%CI=1.315-9.776, p = 0.013). On the other hand, older patients had unchanged or improved seizures compared to younger ones (OR=0.889, 95%CI=0.799-0.990, p = 0.032).

Table 2
Views of caregivers on different issues related to COVID-19 pandemic

| Views of parents | Number (%) |
|------------------|------------|
| Do you think that COVID-19 outbreaks prevent your child from getting proper epilepsy care? | 52 (33.8) |
| • No | 102 (66.2) |
| • Yes | 44 (28.6) |
| Difficulty giving ASMs to the child on time because of loss of daily routine during COVID-19 pandemic | 110 (71.4) |
| • No | 46 (29.9) |
| • Yes | 64 (42.2) |
| Difficulty obtaining ASMs during the pandemic | 115 (74.7) |
| • No | 39 (25.3) |
| • Yes | 86 (55.8) |
| Do you think your child with epilepsy would benefit from the COVID-19 vaccine? | 114 (74) |
| • No | 40 (26) |
| • Yes | 74 (50) |
| Are you willing to vaccinate your child with epilepsy if it is available? | 114 (74) |
| • No | 40 (26) |
| • Yes | 74 (50) |

ASMs: Antiseizeur medicines.

4. Discussion

To the best of our knowledge, this is the first study that investigated prevalence and factors affecting seizure control during the COVID-19 pandemic in children with epilepsy. The results of our study revealed three main findings. First, about a quarter of patients with epilepsy had worsened seizure control during the COVID-19 pandemic in Jordan. Second, the major factors influencing the seizure worsening include the number of antiseizeur medicines taken by patients, age, residency area, and the difficulty in giving the medicine because of loss of daily routine during the COVID-19 pandemic. Third, more than half of caregivers reported difficulty obtaining antiseizeur medicines for their children during the pandemic.

During the COVID-19 pandemic in Jordan, 22.7% of our subjects with epilepsy reported worsened seizure control. On the other hand, the worsening seizure control in previous studies was reported in lower prevalence that varied between 6% and 18% [3, 6, 9, 18, 19]. The high prevalence in our study might be explained by the differences in sample size and age compared to other studies. In addition to that, a high percentage of caregivers reported poor epilepsy care during the COVID-19 pandemic (66.2%). This high percentage was explained by the fact that the lockdown strongly affects daily life, as well as health systems. Therefore, mandatory social distancing and the lack of effective treatments has made telemedicine the safest interactive system between patients and clinicians [16, 20]. Older patients in the present study were found to have more stable seizure control than younger ones (p = 0.032). However, age did not reach statistical significance in previous studies [9, 18]. This finding can be explained by the notion that older patients are usually more independent in dealing with and handling their epilepsy and personal duties, and do not need another individual to obtain or administrate their prescribed medications.
In the current study, patients residing in a villages reported having worsened seizures in comparison to patients residing in cities. This finding is associated primarily with the lower socioeconomic status of individuals residing in a villages [13] and their pre-existing dependence on medical insurances, which primarily covers tertiary hospitals in cities. It has been reported that a higher prevalence of epilepsy and poorer seizure control were associated with low socioeconomic status. Socioeconomic disadvantages among patients with epilepsy might preclude their access to health care including specialty care (because of barriers such as cost and transportation), thus affecting seizure control [13].

Considering the implementation of complete and partial lockdowns and the inability of individuals to freely travel without restrictions between cities, it was likely that subjects could not follow up with their health care providers, where they have been insured. Moreover, the fact that public hospitals and outpatient clinics had to close for months and knowing that 74% of our subjects had a monthly income of less than 600JOD, suggests that it would be difficult for them to seek medical care at the private sector.

In the present study, patients treated with 2 and more antiseizure medicines were associated with worsened seizure control. Remarkably, it was even the strongest predicting factor of seizure worsening ($p < 0.001$) which is consistent with a study in Italy. This probably reflects a concomitant drug resistance and pre-existing difficulty of seizure control [3]. In addition, it has been reported that the number of antiseizure medicines before the pandemic is an indicator of the severity and uncontrollable nature of epilepsy in adult and children studies [3, 6, 14, 17]. Moreover, there is possibility that seizure worsening during the pandemic resulted in prescribing more antiseizure medicines.

In the current study, 71.4% of patients’ caregivers reported having given medicine to their children regularly during the COVID-19 period, whereas 28.6% of patients’ caregivers reported reduced adherence to ASMs as they found difficulty in giving the medicine to their children on time because of loss of daily routine during COVID-19 pandemic. This high percentage of adequate adherence to ASMs is consistent with two previous studies from Italy [3, 6, 19]. This finding can be due to how the presence of the patients in their homes with their families contributed to better monitoring and administration of antiseizure medicines due to a lack of possible distracting factors (e.g. work, school, or recreational and leisure activities), also, the caregivers may have spent more time in taking care and monitoring their children closely at home, thus, achieving more adherence to ASMs, thus achieving better seizure control [3, 18]. Moreover, we found that difficulty in giving the medication was significantly associated ($p = 0.002$) with worsened seizure control.

More than half of caregivers (55.8%) reported difficulty obtaining antiseizure medicines (ASMs) for their children. Although this factor did not reach statistical significance in the current study, this number is really concerning and much higher than other countries such as Italy, (12.6% and 15.3% in adult and pediatric studies respectively) [3, 19], and New York (9.6%) where respondents reported difficulty obtaining ASMs [18]. It is worth mentioning that more than half (52.3%) of caregivers who had a problem getting ASMs attributed this to the difficulty in getting to the hospital to dispense the medications due to the implemented lockdown measures. Another reason reported by 36% of caregivers was that the pharmacy did not have medicine in stock. These findings suggest the feasibility to associate the lockdowns and travel restrictions with medication dispensing and thus affecting the appropriate management and health outcomes of chronic diseases, including epilepsy.

A previous study in Jordan reported that only 37.4% of the 3100 participants were willing to take the COVID-19 vaccine [5]. In the current study, 25.3% of caregivers believed that the vaccine will be beneficial for their children and only 26% of participants were willing to give the vaccine to their children. Further assessment to know which sources people are using, and what misconceptions they might have developed regarding the vaccine will be helpful for the development of public awareness programs surrounding this issue.

This study had some limitations. First, it is a cross-sectional questionnaire survey that records the caregivers’ experiences at only one point in time and thus the answers are given retrospectively. Moreover, many patients’ caregivers do not keep a seizure diary about seizure counts, severity, and hospital visits. Secondly, epilepsy is not a static disease as seizure control has natural fluctuations irrespective of the pandemic, and likely they would have experienced improved or worsened seizure control. Finally, the data was self-reported and subjected to recall and social desirability biases.

5. Conclusion

The novelty of social restriction and lockdowns caused by the COVID-19 pandemic negatively impacted the healthcare system and epilepsy care in Jordan. Among the factors studied, it was found that the number of chronically taken antiseizure medicines is the strongest predicting factor of seizure worsening in pediatric patients. In addition, the other factors affected the seizure control during COVID-19 were age, residency area, and the difficulty in giving the medication. Moreover, large number of caregivers reported an increased in difficulty obtaining antiseizure medicines for their children during the pandemic. These findings highlight the need to improve epilepsy care in Jordan through the implementation of organized and efficient telemedicine programs devoted to epilepsy care. Moreover, the alarming socioeconomic disadvantages that were aggravated by the COVID-19 pandemic should be studied to find ways to limit their effect on access to necessary medical care.
Table 3
Factors affecting seizure control during the COVID-19 pandemic.

| Factors                        | Univariate analysis Stable or better seizure control NoN=119 | Worse seizure control YesN=35 | P value | Multivariate analysis OR (95% CI) | P value |
|--------------------------------|-------------------------------------------------------------|--------------------------------|---------|-----------------------------------|---------|
| Age                            | 10 [6-13]                                                   | 4 [3-11]                       | 0.001   | 0.889 (0.799-0.990)               | 0.032   |
| Gender                         |                                                            |                                |         |                                   |         |
| - Male                         | 64 (53.8)                                                   | 21 (60)                        | 0.515   |                                   |         |
| - Female                       | 55 (46.2)                                                   | 14 (40)                        |         |                                   |         |
| Duration of disease<sup>c</sup> | 3 [2-7]                                                     | 3 [1.2-6]                      | 0.442   |                                   |         |
| Education of parents           |                                                            |                                |         |                                   |         |
| - School education             | 56 (47.1)                                                   | 25 (71.4)                      | 0.011   | Ref                               | 0.058   |
| - University education         | 63 (52.9)                                                   | 10 (28.6)                      |         | 0.339 (0.111-1.039)               |         |
| Income                         |                                                            |                                |         |                                   |         |
| - < 600 JOD<sup>c</sup>       | 83 (69.7)                                                   | 31 (88.6)                      | 0.026   | Ref                               | 0.213   |
| - ≥ 600 JOD<sup>c</sup>       | 36 (30.3)                                                   | 4 (11.4)                       |         | 0.423 (0.109-1.640)              |         |
| Employment                     |                                                            |                                | 0.077   |                                   |         |
| - Unemployed                   | 58 (48.7)                                                   | 23 (65.7)                      |         |                                   |         |
| - employed                     | 61 (51.3)                                                   | 12 (34.3)                      |         |                                   |         |
| Achievement of seizure control before outbreak |                                |                                | 0.072   |                                   |         |
| - No                           | 35 (29.4)                                                   | 16 (45.7)                      |         |                                   |         |
| - Yes                          | 84 (70.6)                                                   | 19 (54.3)                      |         |                                   |         |
| Residency area                 |                                                            |                                |         | 0.013                             |         |
| - city                         | 66 (55.5)                                                   | 12 (34.3)                      |         | Ref                               |         |
| - village                      | 53 (44.5)                                                   | 23 (65.7)                      |         | 3.585 (1.315-9.776)              |         |
| Health insurance               |                                                            |                                | 0.035   | 0.502                             |         |
| - Not insured                  | 38 (31.9)                                                   | 18 (51.4)                      |         | Ref                               |         |
| - Insured                      | 81 (68.1)                                                   | 17 (48.6)                      |         | 1.460 (0.483-4.413)              |         |
| Number of ASMs                 |                                                            |                                |         |                                   |         |
| - One medication               | 70 (58.8)                                                   | 5 (14.3)                       | < 0.001 | Ref                               | < 0.001 |
| - ≥ 2 medications             | 49 (41.2)                                                   | 30 (85.7)                      |         | 10.512 (3.105-35.587)            |         |
| Difficulty giving medicines to your child on time because of loss of daily routine during COVID-19 pandemic | 93 (78.2)                                                   | 17 (48.6)                      | 0.001   | 0.002                             |         |
| - No                           | 26 (21.8)                                                   | 18 (51.4)                      |         | Ref                               |         |
| - Yes                          | 67 (51.3)                                                   | 25 (71.4)                      |         | 0.957 (0.303-3.026)              | 0.941   |
| Difficulty obtaining ASMs during the pandemic |                                |                                | 0.035   |                                   |         |
| - No                           | 58 (48.7)                                                   | 10 (28.6)                      |         | Ref                               |         |
| - Yes                          | 61 (51.3)                                                   | 25 (71.4)                      |         | 0.957 (0.303-3.026)              | 0.941   |
| Years of medications treatment<sup>b</sup> | 3 [1-6]                                                      | 3.5 [2-5.25]                   | 0.131   | 0.160                             |         |
| type of epilepsy                |                                                            |                                |         |                                   |         |
| - Focal                        | 53 (44.5)                                                   | 15 (42.9)                      |         | 0.160                             |         |
| - Generalized                  | 39 (32.8)                                                   | 7 (20)                         |         |                                   |         |
| - Unclassified                 | 27 (22.7)                                                   | 13 (37.1)                      |         |                                   |         |
| Presence of comorbid condition |                                                            |                                | 0.129   |                                   |         |
| - No                           | 96 (80.7)                                                   | 24 (68.6)                      |         |                                   |         |
| - Yes                          | 23 (19.3)                                                   | 11 (31.4)                      |         |                                   |         |

CI: confidence interval; OR: odds ratio.
<sup>a</sup> Data are presented as number (percent) unless otherwise indicated.
<sup>b</sup> median [interquartile range].
<sup>c</sup> 1 JOD = 1.42 US dollars.

care in similar times.

Funding
This research was supported by the Deanship of Research, Jordan university of Science and Technology, Irbid, Jordan [Grant number 907/2020].

Declaration of Competing Interest
All named authors declare that they have no potential conflict of interest.

References
[1] Al-Qudah AA, Albsoul-Younes A, Masri AT, AbuRahmah SK, Alabadi IA, Nafi OA, et al. Type and etiology of pediatric epilepsy in Jordan. A multi-center study. Neurosciences (Riyadh) 2017;22(4):267-73.
[2] AlSamman M, Caggiula A, Ganguli S, Misak M, Pourmand A. Non-respiratory presentations of COVID-19, a clinical review. Am J Emerg Med 2020;38(11):2444-54.
[3] Assenza G, Lanzone J, Brigo F, Coppola A, Di Gennero G, Di Lazzaro V, et al. Epilepsy care in the time of COVID-19 pandemic in Italy: risk factors for seizure worsening. Front Neurol 2020;11:737.
[4] Bahou YG, Jaber MS, Kasabeh AS. Quality of life in epilepsy at Jordan University Hospital. Neurosciences (Riyadh) 2011;16(1):18–23.
[5] El-Elimat T, AbuAlSamen MM, Almomani BA, Al-Sawalha NA, Alali FQ. Acceptance and attitudes toward COVID-19 vaccines: a cross-sectional study from Jordan. PloS One 2021;16(4):e0250555.
[6] Gul ZB, Atakli HD. Effect of the COVID-19 pandemic on drug compliance and stigmatization in patients with epilepsy. Epilepsy Behav 2021;114(Pt A):107610.
[7] Gutter T, Callenbach PMC, Brouwer OF, de Weerd AW. Prevalence of sleep disturbances in people with epilepsy and the impact on quality of life: a survey in secondary care. Seizure 2019;69:298–303.

[8] Helms J, Kremer S, Merdji H, Clerc-Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 2020;382(23):2266–70.

[9] Huang S, Wu C, Jia Y, Li G, Zhu Z, Lu K, et al. COVID-19 outbreak: the impact of stress on seizures in patients with epilepsy. Epilepsia 2020;61(9):1884–93.

[10] Kayed M. Schools suspended, borders closed, gatherings banned as gov’t responds to continued coronavirus spread. The Jordan Times 2020.

[11] Keyhanian K, Umeton RP, Mobiti B, Davoudi V, Hajighasemi F, Ghasemi M. SARS-CoV-2 and nervous system: from pathogenesis to clinical manifestation. J Neuroimmunol 2020;350(577436):577436.

[12] La Torre G, Massetti AP, Antonelli G, Fantini M, Marte M, et al. Anosmia and ageusia as predictive signs of COVID-19 in healthcare workers in Italy: a prospective case-control study. J Clin Med 2020;9(9):2870.

[13] Ma TM, Ma TM, Lebo GM, Nkosi MM, Madinga J, Kola CK, et al. Are the children with epilepsy treated traditionally a disadvantaged group? A pilot study. Pan Afr Med J [Internet] 2016;23. https://doi.org/10.11604/pamj.2016.23.229.9165. Available from.

[14] Nair DR. Management of drug-resistant epilepsy. Continuum (Minneap Minn), Epilepsy 2016;22(1):157–72.

[15] Neubauer BA, Gross S, Hahn A. Epilepsy in childhood and adolescence. Dtsch Arztebl Int 2008;105(17):31907. quiz 327–8.

[16] Pasca L, Zanaboni MP, Grumi S, Totaro M, Ballante E, Varesio C, De Giorgio V. Impact of COVID-19 pandemic in pediatric patients with epilepsy with neuropsychiatric comorbidities: a telemedicine evaluation. Epilepsy Behav Feb 2021;115:107519. https://doi.org/10.1016/j.yebeh.2020.107519. Epub 2020 Nov 28. PMID: 33207293; PMCID: PMC7695947.

[17] Poudel P, Chitlangia M, Pokharel R. Predictors of poor seizure control in children managed at a tertiary care hospital of eastern Nepal. Iran J Child Neurol 2016;10 (3):48–56, Summer.

[18] Roseangeli JL, Donato J, Ferasteroa V, Zhao D, Molinero I, Boro A, et al. Seizure control, stress, and access to care during the COVID-19 pandemic in New York City: the patient perspective. Epilepsia 2021;62(1):41–50.

[19] Trivisano M, Specchio N, Pietrafusa F, Calabrese G, Ferretti A, Ricci R, et al. Impact of COVID-19 pandemic on pediatric patients with epilepsy - The caregiver perspective. Epilepsy Behav 2020;113(107527):107527.

[20] von Wrede R, Moskau-Hartmann S, Baumgartner T, Helmsstaedter C, Surges R. Counseling of people with epilepsy via telemedicine: experiences at a German tertiary epilepsy center during the COVID-19 pandemic. Epilepsy Behav Nov 2020;112:107298. https://doi.org/10.1016/j.yebeh.2020.107298, Epub 2020 Aug 12. PMID: 32801068; PMCID: PMC7422810.